C. Bulaï Livideanu
A5001448942- Mast cells and histamine
- Urticaria and Related Conditions
- Autoimmune Bullous Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Drug-Induced Adverse Reactions
- melanin and skin pigmentation
- Eosinophilic Disorders and Syndromes
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Allergic Rhinitis and Sensitization
- Dermatologic Treatments and Research
- Cutaneous lymphoproliferative disorders research
- Immunodeficiency and Autoimmune Disorders
- Nail Diseases and Treatments
- Syphilis Diagnosis and Treatment
- Skin Diseases and Diabetes
- Chemotherapy-related skin toxicity
- Autoimmune and Inflammatory Disorders
- Genetic and rare skin diseases.
- Pharmaceutical studies and practices
- Systemic Lupus Erythematosus Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hidradenitis Suppurativa and Treatments
- Monoclonal and Polyclonal Antibodies Research
Centre Hospitalier Universitaire de Toulouse
2016-2025
Hôpital Larrey
2016-2025
Inserm
2012-2025
Université Toulouse III - Paul Sabatier
2016-2025
Centre National de la Recherche Scientifique
2012-2025
Université de Toulouse
2013-2024
Centre de Recherche en Mathématiques de la Décision
2023-2024
Centre de Référence des Maladies Autoinflammatoires et des Amyloses
2024
Institut Toulousain des Maladies Infectieuses et Inflammatoires
2023
John Wiley & Sons (United States)
2019
BackgroundIndolent systemic mastocytosis (ISM) is a clonal mast-cell disease driven by the KIT D816V mutation. We assessed efficacy and safety of avapritinib versus placebo, both with best supportive care, in patients ISM.MethodsWe randomized moderate to severe ISM (total symptom score [TSS] ≥28; scores range from 0 110, higher numbers indicating more symptoms) two one 25 mg once daily (n=141) or placebo (n=71). The primary end point was mean change TSS based on 14-day average...
Systemic mastocytosis with associated hematologic clonal non-mast cell disease (SM-AHNMD) is a rare and heterogeneous subtype of SM few studies on this specific entity have been reported. Sixty two patients were presented. Myeloid AHNMD was the most frequent (82%) cases. This subset older, had more cutaneous lesions, splenomegaly, liver enlargement, ascites; lower bone mineral density hemoglobin levels higher tryptase level than lymphoid AHNMD. Defects in KIT, TET2, ASXL1 CBL positive 87%,...
Two pemphigus severity scores, Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI), have been proposed to provide an objective measure of disease activity. However, the use these scores in clinical practice is limited by absence cut‐off values that allow differentiation between moderate, significant extensive types pemphigus. To calculate defining based on ABSIS PDAI scores. In 31 dermatology departments six countries, consecutive patients with...
Genital psoriasis is often under-recognized.To assess the instantaneous prevalence of genital and describe its clinical features, association with a particular subtype impact on general sexual quality life (QoL).GENIPSO prospective study conducted by private hospital-based dermatologists. This featured consecutive inclusion patients consulting for extragenital psoriasis. The features were recorded QoL health questionnaires distributed to patients.Overall, 335 776 (43·2%) included in had...
Abstract Background Biological agents targeting IL ‐17 are very effective for clearing moderate to severe psoriasis. There is limited information regarding the frequency and pattern of psoriasis relapse upon treatment cessation. Objective To investigate recurrence in patients who were treated with brodalumab following Amgen's decision stop clinical programme June 2015. Materials methods Between 2015 March 2016, we constructed a retrospective multicenter cohort study including protocols after...
Dear Editor, Beck et al. [1] recently identified a genetic disorder that connects seemingly unrelated adult-onset inflammatory syndromes as VEXAS syndrome. We report case of syndrome in patient with previous SpA favourable response to i.v. immunoglobulin and anti-IL17 therapy. In 2010, diagnosis was made 57-year-old man, who had back pain, peripheral arthritis, bilateral active sacroiliitis on MRI (Fig. 1A) HLA- B27–positive testing [2]. After failure several NSAIDs, the initiation anti-TNF...
BackgroundMastocytosis and monoclonal mast cell (MC) activation syndrome (MMAS) are heterogeneous conditions characterized by the accumulation of atypical MCs. Despite recurrent involvement KIT mutations, pathophysiologic origin mastocytosis MMAS is unclear. Although hereditary α-tryptasemia (HαT, related to TPSAB1 gene duplication) abnormally frequent in these diseases, it not known whether association coincidental or causal.ObjectiveWe evaluated prevalence HαT all subtypes assessed with...